DOCSLIB.ORG

Thomas N. Denny January 2017

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Thomas N. Denny January 2017 DUKE UNIVERSITY MEDICAL CENTER CURRICULUM VITAE Thomas N. Denny January 2017 PRIMARY ACADEMIC APPOINTMENT(s): Professor of Medicine 2010 – present Department of Medicine, Duke School of Medicine Duke University Medical Center Durham, North Carolina Chief Operating Officer 2006 – present Duke Human Vaccine Institute and Center for HIV/AIDS Vaccine Immunology Duke School of Medicine, Duke University Durham, North Carolina Director 2006 – present Duke Human Vaccine Institute- Immunology Quality Assessment Center Duke School of Medicine, Duke University Durham, North Carolina SECONDARY APPOINTMENT(s): Member, Health Sector Advisory Board 2010-present Duke Fuqua School of Business Duke University Durham, North Carolina Member, Duke Center for AIDS Research 2006 – present Duke School of Medicine Duke University Durham, North Carolina Member, Duke Global Health Institute 5/1/13 - present Duke University Durham, North Carolina (Affiliate Member, Duke Global Health Institute 2009-2013) PRESENT ACADEMIC RANK AND TITLE Professor of Medicine DATE AND RANK OF FIRST DUKE FACULTY Temporary Instructor/ Associate Professor, APPOINTMENT Track 5, May 2006 MEDICAL LICENSURE N/A Thomas N. Denny page 1 of 43 CITIZENSHIP United States EDUCATION INSTITUTION DATE/YEAR DEGREE High School St. Thomas More High 1972 Diploma School Philadelphia, PA College Pennsylvania State 1975 Bachelor of Science (B.S.), University Biology GRADUATE/PROFESSIONAL SCHOOL Master of Science (M.Sc.), Molecular and Biomedical Immunology 2001 University of East London, Faculty of Sciences and Health, London, United Kingdom Thesis: Immunological Assessment of Maternal and Fetal Baboon Immunoregulatory Cells MASTER IN MEDICAL LAW (M. Phil), Beginning of Life and Genetic Issues 2010 Institute of Law and Ethics in Medicine, School of Law, University of Glasgow, Glasgow, Scotland Thesis: Contemporary Science and Old Traditions: Stem Cell Policies in the United Kingdom and the United States ADDITIONAL GRADUATE WORK: Fourteenth Annual Summer Institute in Management of Nonprofit Organizations 1992 Robert F. Wagner Graduate School of Public Service New York University, New York, New York FELLOWSHIP Robert Wood Johnson Foundation Health Policy Fellow National Academies 2002-2003 Institute of Medicine U.S. Senate Committee on Health, Education, Labor and Pensions (Legislative portfolio: Global HIV/AIDS, Biodefense, Vaccines, Clinical Trials/IRB) http://www.healthpolicyfellows.org/home.php ONGOING TRAINING: Certificate in Isotope Handling, Hahneman Medical College and Hospital 1975 Philadelphia, Pennsylvania Development of the Saginaw Community Cancer Center Research Laboratory, 1976 Saginaw, Michigan: A Satellite Campus of Michigan State University College of Human Medicine Participant in the American Society of Clinical Pathologists Continuing Education 1979 Program Research Diving Program, Bermuda Biological Station for Research, St. Georges 1981 West, Bermuda Annual Course in Flow Cytometry, Applications in Immunobiology and Cell 1987 Biology, Los Alamos National Laboratory, Los Alamos, New Mexico Strategic Management Program, The Wharton School, University of Pennsylvania, 1991 Thomas N. Denny page 2 of 43 Philadelphia, Pennsylvania Program for Advanced Training in Biomedical Research Management, Harvard 1993 School of Public Health, Boston, Massachusetts Design Principles for Immune System and Other Distributed Autonomous 1999 Systems, Santa Fe Institute, Santa Fe, New Mexico Human Subject Participant Protection Training Certification, Investigational Review 2001 Board New Jersey Medical School, Newark, New Jersey Intensive Bioethics Course XXIX – A Brave New World The Kennedy Institute of 2003 Ethics, Georgetown University, Washington, DC Leadership Academy, New Jersey Medical School, Newark, New Jersey 2003 SCHOLARLY SOCIETY Sigma Xi, The Scientific Research Society 1987 PROFESSIONAL TRAINING AND ACADEMIC CAREER: Institution Position/Title Dates University of Pennsylvania, Research Assistant 1973–1974 Philadelphia, PA Department of Pathology, Veterinary Medical College Hahneman Medical College and Research Assistant 1974–1975 Hospital, Philadelphia, PA Department of Surgery and Medicine, Hematology / Oncology Section American Red Cross, Lansing, MI Research Assistant 1975–1977 Michigan State University, Senior Research Assistant 1975–1979 East Lansing, MI Oncology / Hematology Laboratory, Department of Medicine, College of Human Medicine Capital Area Career Center, Instructor 1977–1979 Mason, MI Department of Allied Health Sloan Kettering Institute, Memorial Senior Research Assistant 1979–1983 Sloan-Kettering Cancer Center, Developmental Immunobiology, Cell New York, NY Engineering and Cancer Immunotherapy Section Laboratory and Lymphocyte Surface Marker Laboratory UMD-New Jersey Medical School, 1983-2006 As Follows: Newark, NJ Research Teaching Specialist II, 1983–1986 Laboratory Supervisor Division of Allergy, Immunology and Infectious Diseases, Department of Pediatrics Director of Research Administration and 1986-1992 Laboratory Services Division of Allergy, Immunology and Infectious Diseases, Department of Pediatrics Associate in Pediatrics 1987-1997 Thomas N. Denny page 3 of 43 Director, Center for Laboratory 1990-2006 Investigation Division of Allergy, Immunology and Infectious Diseases, Department of Pathology, Laboratory Medicine and Pediatrics Executive Director Division of Allergy, 1992-2003 Immunology and Infectious Diseases, Department of Pediatrics New Jersey Medical School Assistant Professor of Pathology 1997-2002 Laboratory Medicine and Pediatrics Associate Professor of Pathology, 2003-2006 Laboratory Medicine and Pediatrics Assistant Dean for Research in Health 2003-2006 Policy Associate Professor of Preventive 2005-2006 Medicine and Community Health PROFESSIONAL ACTIVITIES Consultant Becton Dickinson Immunocytometry 1989-1990 Systems, San Jose, California Consultant Coulter Immunology, Coulter 1991-1992 Incorporated, Miami, Florida Consultant Ministry of Health, Republic Kalmykia, 1991-2006 Halmg Tangche, Russia, (Former Soviet Union) Guest Editor Clinical Immunology Newsletter. 1992 Pediatric HIV Infection: Epidemiology, Treatment and Laboratory Diagnosis. Vol. 12 #6 Editor Immunology Updates, Publisher 1992-1993 Norman E. Williams, Wyckoff, New Jersey Consultant Abbott Laboratories Diagnostics 1992-1994 Division, Abbott Park, Illinois Consultant Zynaxis Cell Sciences, Malvern, 1992-1996 Pennsylvania Ad Hoc Reviewer Journal of Clinical Immunology and 1992– present Immunopathology, Clinical Infectious Diseases and Journal of International Infectious Diseases Editor Pediatric HIV Forum, Publisher Norman 1993-1995 E. Williams, Wyckoff, New Jersey Member Editor Board Communications in Clinical Cytometry 1993 - present (re-appointed 1998) Thomas N. Denny page 4 of 43 Consultant Lviv Regional Specialized Children’s 1993-2006 Hospital of Chernobyl, Lviv, Ukraine, (Former Soviet Union) Member, Special Review Committee AIDS P-94-25B- Master Agreement for 1994 Preclinical Vaccine Development, National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland Participant, Working Group Pneumocystis carinii Prophylaxis for 1994 Infants and Children At-Risk for HIV, Centers for Disease Control, Atlanta, Georgia Member, Conference Scientific Sixth International Conference on 1994 Program Committee Human Retrovirology: HTLV, Absecon, New Jersey Consultant Serono Laboratories, Inc., Norwell, 1994-1995 Massachusetts Consultant Biometric Imaging, Mountain View, 1994-1996 California Member Editorial Board Clinical Diagnostic and Laboratory 1994-2005 Immunology (re-appointed 1999 and 2002) Member, Cellular Diagnostic Advisory Abbott Laboratories Diagnostics 1994-1997 Panel Division, Abbott Park, Illinois Visiting Scientist Pedro Kouri Institute of Tropical 1995 Infectious Diseases, Havana, Cuba Consultant Bio Delivery Systems International, 1995-2005 Newark, New Jersey Member, Advisory Board Frontier Science and Technology 1995-1998 Research Foundation, Amherst, New Jersey Member, International Scientific The XI International Conference on 1996 Committee for Clinical Science AIDS, Vancouver, British Colombia Consultant Smith – Kline Beecham 1997-1999 Pharmaceuticals, Philadelphia, Pennsylvania Member, International Scientific The XII International Conference on 1998 Committee for Clinical Science AIDS, Geneva, Switzerland Member, Special Emphasis Panel Acute Infection and Early Disease 1998 PAR 96-060 Research Network (AIEDRN) Development, National Institutes of Health, National Institute of Allergy, and Infectious Diseases, Bethesda, Maryland Member, International Scientific The XIII International Conference on 2000 Committee for Clinical Science AIDS, Durbin, South Africa Thomas N. Denny page 5 of 43 Member Editorial Board Clinical and Applied Immunology 2000-2006 Reviews Member, Special Emphasis Panel Center for Scientific Review, National 2001 Review Group ZRG1 Institutes of Health, Department of Health and Human Services, Bethesda, Maryland Member, Special Review Group for Adult AIDS Clinical Trials Group, 2003 Immunology Support Laboratories National Institutes of Health, Bethesda, Maryland Member, Special Emphasis Panel Center for Scientific Review, National 2003 Review Group ZRG1 Institutes of Health, Department of Health and Human Services, Bethesda, Maryland Consultant Centers for Disease Control, 2003-2007 GAP/PEPFAR HIV Maternal to Child Transmission Program – Guyana Associate Editor Immunology Section American
Load more

Recommended publications
  • 1 the Forgotten Viruses Before There Was HIV There Was HTLV, The
    The Forgotten Viruses Before there was HIV there was HTLV, the Human T-Cell Leukemia Virus. In 1983, Robert Gallo and Luc Montagneir independently discovered the viral agent responsible for AIDS and called the newly discovered virus HTLV-3 and LAV, respectively. The name was eventually changed to HIV—Human Immunodeficiency Virus—but Gallo’s initial use of the HTLV-3 tag is a reminder that two other HTLVs were known at the time. Three years earlier, Gallo had isolated the first human retrovirus from patients with T-cell leukemia/lymphoma. This was HTLV-1. A year later, a second cancer-causing retrovirus (HTLV-2) was found. The wealth of nations and a generation of scientists were directed at uncovering the mysteries of HIV’s origins, genetics, epidemiology, and disease-causing properties. Thirty years later, many of those mysteries have been solved even as lingering questions have attracted the attention of a new generation of scientists and physicians. AIDS and HIV have cast a long, dark shadow over science and societies; still hidden in that 30-year-old shadow are the HTLVs. They may have been forgotten by the public and many researchers, but these cancer-causing viruses did not disappear. It is likely they have infected 20 million people worldwide and, in the absence of effective drugs and preventive vaccines, they continue to spread, causing significant sickness and death. HTLV-1 causes two awful diseases: Adult T-cell Leukemia/Lymphoma (ATLL), and HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP). Though many HTLV-1 patients are carriers only and show no symptoms, they remain capable of transmitting the virus to others through blood donations, sex, and breastfeeding.
    [Show full text]
  • Skidmore College 2001-2002 Catalogue
    Nonprofit Organization Skidmore College Catalog 2001-2002 U.S.Postage Paid Skidmore College Office of Admissions Skidmore Skidmore College 815 North Broadway Saratoga Springs New York 12866-1632 College 2001 2002 Directory for Correspondence SKIDMORE COLLEGE 815 NORTH BROADWAY SARATOGA SPRINGS, NEW YORK 12866-1632 Information: 518-580-5000 Automated Operator: 518-580-7400 World Wide Web: www.skidmore.edu General College Policy ...... Jamienne S. Studley, President Academic Policy ....... John J. Berman, Dean of the Faculty Student Affairs .............................. Thomas P. Oles, Dean Student Academic Affairs .... Jon Ramsey, Dean of Studies Admissions ....... Mary Lou Bates, Dean of Admissions and ............................................................................ Financial Aid Financial Aid ................................. Robert Shorb, Director Financial Services ...................................... TBA, Director Records and Transcripts ...........Ann Henderson, Registrar Career Services .......................... Michael Profita, Director Alumni Activities ....................... Michael Sposili, Director College Relations ....................Robert Kimmerle, Director Opportunity Programs..............Susan B. Layden, Director Diversity and Affirmative Action ................................................... Jack T. F. Ling, Director 2001-2002 CATALOG © Skidmore College, 2001 Skidmore College endeavors to present an accurate overview of its curricular and cocurricular programs, facilities, and fees in this publication.
    [Show full text]
  • Moving Higher and Higher: Creating Building Blocks for the Future
    university of maryland school of medicine Moving Higher and Higher: Creating Building Blocks for the Future 2008 state of the OUR MISSION school address the university of maryland school of medicine is dedicated to providing excellence in biomedical education, basic and clinical research, quality patient care and service to improve the health of the citizens of maryland and beyond. the school is committed to the education and training of md, md/phd, graduate, physical therapy and rehabilitation science, and medical research technology students. we will recruit and develop faculty to serve as exemplary role models for our students. University of Maryland School of Medicine 655 West Baltimore Street • Baltimore, Maryland 21201 • http://medschool.umaryland.edu E. Albert Reece, MD, PhD, MBA Vice President for Medical Affairs, University of Maryland John Z. and Akiko K. Bowers Distinguished Professor and Dean, University of Maryland School of Medicine 2008 STATE OF THE SCHOOL ADDRESS The theme of this year’s address is These building blocks are interde- “Moving Higher and Higher: Creating pendent and when placed at the right Building Blocks for the Future.” place at the right time, they will build our Building blocks are a collection of tower even higher. We believe that this components designed to elevate and analogy can be aptly applied to the School typically build a structure, and they are of Medicine, where our efforts, our goals, used here to represent various aspects our partnerships, our determination, of the School of Medicine’s mission and our relentless pursuit of excellence are indeed interdependent, and when areas. As the building blocks of our harnessed properly, will propel this mission areas are assembled, they are medical school to even greater heights.
    [Show full text]
  • Meeting Program SID 2019 ANNUAL MEETING
    Meeting Program SID 2019 ANNUAL MEETING 2019 Annual Meeting Scientific 2019 Annual Meeting Program Chairs, Committee Committee on Education Members, and Reviewers Chairs and Committee CHAIRS Members Dan Kaplan, MD/PhD, University of Pittsburgh CHAIRS Ethan Lerner, MD/PhD, Mass General Hospital Heidi Kong, MD, National Insitutes of Health Todd Ridky, MD/PhD, University of Pennsylvania COMMITTEE MEMBERS Lloyd Miller, MD/PhD, Johns Hopkins University COMMITTEE MEMBERS Kevin Wang, MD/PhD, Stanford University My Mahoney, PhD, Thomas Jefferson University Spiro Getsios, PhD, Aspect Biosystems Alexander Marneros, MD/PhD, Harvard University Peggy Myung, MD/PhD, Yale University Robert Dellavalle, MD/PhD, University of Colorado Marjana Tomic-Canic PhD, University of Miami Amanda MacLeod, MD, Duke University Vladimir Botchkarev, MD/PhD, Boston University Cristina de Guzman Strong, PhD, Washington University-St. Louis Tissa Hata, MD, University of California, San Diego Maryam Asgari, MD, Massachusetts General Hospital Ken Tsai, MD/PhD, Moffitt Cancer Center and Paul Nghiem, MD/PhD, University of Washington Research Institute Richard Granstein, MD, Weill Cornell Medical School Sarah Millar, PhD, Mt. Sinai Medical School Matthew Vesley, MD/PhD, Yale University REVIEWERS Anna Di Nardo, MD/PhD Jennifer Gill, MD/PhD, University of Texas Southwestern Carolyn Lee, MD/PhD Jonathan Silverberg, MD/PhD ACKNOWLEDGEMENTS Bogi Andersen, MD The organizers of the 2019 SID Annual Meeting gratefully Kavita Sarin, MD/PhD acknowledge the sponsors, exhibitors, and participants whose Peter Koch, PhD Tiffany C. Scharschmidt, MD attendance has helped to make this meeting possible. Joseph Merola, MD Sakeen Kashem, MD/PhD Thomas Hultsch, MD Amanda MacLeod, MD Liang Deng, MD/PhD Ya-Chieh Hsu, PhD Crystal Aguh, MD Katherine Radek, PhD Paul Nghiem, MD/PhD Alicia Mathers, PhD Raymond Cho, MD Zelma Chiesa, MD Anna Mandinova, MD/PhD Brian Capell, MD/PhD Ryan R.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,699,656 B2 Gallo Et Al
    USOO6699656B2 (12) United States Patent (10) Patent No.: US 6,699,656 B2 Gallo et al. (45) Date of Patent: *Mar. 2, 2004 (54) TREATMENT AND PREVENTION OF HIV 5,451.527 9/1995 Sarin et al. INFECTION BY ADMINISTRATION OF 5,494,899 2/1996 Kincade et al. DERVATIVES OF HUMAN CHORONIC 5,508.261 4/1996 Moyle et al. GONADOTROPIN 5,610,136 3/1997 McMichael 5,614.612 3/1997 Hagiwood et al. 5,635,599 6/1997 Pastan et al. (75) Inventors: Robert C. Gallo, Bethesda, MD (US); 5,650,390 7/1997 Samaritani et al. ......... 244/575 Joseph Bryant, Rockville, MD (US); 5,674,983 10/1997 Blithe et al. .................. 448/79 Yanto Lunardi-Iskandar, Gaithersburg, 5,677.275 10/1997 Lunardi-Iskandar et al. MD (US) 5,700,781 12/1997 Harris 5,811,390 9/1998 Bourinbaiar (73) Assignee: University of Maryland Biotechnology 5,817,753 10/1998 Stevens ...................... 958/601 Institute, Baltimore, MD (US) 5,877,148 3/1999 Lunardi-Iskandar et al. ... 514/8 5,968,513 10/1999 Gallo et al. (*) Notice: Subject to any disclaimer, the term of this 5.997,871 12/1999 Gallo et al. patent is extended or adjusted under 35 6,319,504 B1 11/2001 Gallo et al. U.S.C. 154(b) by 0 days. FOREIGN PATENT DOCUMENTS EP O O49898 B2 4/1982 This patent is Subject to a terminal dis EP O 142387 A1 5/1985 claimer. EP O 211 411 A2 2/1987 EP O323769 11/1988 - - - - - - - - - - - - - - - - - - - - - - - - 7/6 EP O211013 B1 3/1993 (21) Appl.
    [Show full text]
  • Abstract Supplement
    Abstract Supplement FOCIS 2017 1 Federation of Clinical Immunology Societies June 14-17, 2017 Chicago, Illinois FOCIS 2017 Abstract Supplement TABLE OF CONTENTS Abstracts by Subject Area ............................................................................................................................. 2 Allergy/asthma........................................................................................................................................... 2 Autoimmune neurologic diseases .............................................................................................................. 3 Autoimmune rheumatologic diseases ...................................................................................................... 11 Bone marrow or stem cell transplantation ............................................................................................... 32 Cytokines/chemokines ............................................................................................................................ 34 Diabetes and other autoimmune endocrine diseases .............................................................................. 36 Genetics .................................................................................................................................................. 55 Immune monitoring .................................................................................................................................. 59 Immunity & infection ...............................................................................................................................
    [Show full text]
  • Quest for the AIDS Virus
    Dr. Robert Gallo and Secretary Margaret Heckler hold a press confer- ence concerning the cause of AIDS, April 23, 1984. Bettmann / Contributor “Good afternoon, Ladies and Gentlemen. The probable cause of AIDS has been found…Today we add another miracle to the long honor roll of American medicine and science. Today’s discovery represents the triumph of science over a dreaded disease. Those who have disparaged this scientific search—those who said we weren’t doing enough—have not understood how sound, solid, significant medical research proceeds. From the first day that AIDS was identified in 1981, HHS scientists and their medical allies have never stopped searching for the answers to the AIDS mystery. Without a day of procrastination, the resources of the Public Health Service have been effectively mobilized.…Credit must go to our eminent Dr. Robert Gallo [AΩA, Sidney Kimmel Medical College, 1962], who directed the research that produced this discovery.” —Margaret Heckler, Secretary of Health and Human Services (HHS), April 23, 1984, Washington, DC Quest for the AIDS virus Harry W. Haverkos, M.D. Dr. Haverkos is Captain (retired), United States Public study among men in Atlanta, Los Angeles, New York City, Health Service; and Associate Professor, Preventive and San Francisco was conducted.1 Medicine and Biostatistics, Uniformed Services The study identified the two leading risk factors for University of the Health Sciences, Bethesda, Maryland. Kaposi’s sarcoma and/or Pneumocystis carinii pneumo- nia (PCP) as the lifetime number of sexual partners, and n July 1981, I entered the Epidemic Intelligence Service meeting partners in bathhouses.2,3 Those results suggested (EIS) of the Centers for Disease Control (CDC) and that a novel sexually transmitted agent was involved, and Iwas immediately recruited by James Curran, MD, retroviruses soon became a target for the search.
    [Show full text]
  • Craig Venter Vs the Human Genome Project
    BALLEN SCIENTIFIC RIVALRIES AND SCANDALS In the mid-1980s, some geneticists proposed a daring project to sequence the human genome. That meant figuring out the exact order of the three billion chemical pairs that make up human DNA. Sequencing the human genome could help scientists understand how our bodies work and help doctors diagnose, treat, and prevent certain diseases. The HUMAN GENOME PROJECT launched in 1990, with scientists around the world collaborating on the research. They worked slowly and methodically, trying to produce the most accurate information possible. By 1991 one of these scientists, CRAIG VENTER, became fed up with the HGP’s slow pace. He challenged the HGP to move faster and started his own company to compete with the HGP. OUR DNA OUR Racing neck and neck, the two organizations reached their goal years ahead of OUR schedule. But the challenge also led to a bitter public argument, especially over who could use the sequence and how. This book reveals how ambition, persistence, ego, greed, and principle combined—often with explosive results—in the quest to decode our DNA. READ ABOUT ALL OF THE DNA SCIENTIFIC RIVALRIES AND SCANDALS CRAIG VENTER BATTLE OF THE DINOSAUR BONES: Othniel Charles Marsh vs Edward Drinker Cope DECODING OUR DNA: Craig Venter vs the Human Genome Project THE RACE TO DISCOVER THE AIDS VIRUS: Luc Montagnier vs Robert Gallo THE HUMAN TWENTY-FIRST CENTURY VS WAR OF THE CURRENTS: Thomas Edison vs Nikola Tesla GENOME PROJECT KAREN GUNNISON BALLEN THIS PAGE INTENTIONALLY LEFT BLANK SCIENTIFIC RIVALRIES AND SCANDALS OUR DNA CRAIG VENTER VS THE HUMAN GENOME PROJECT KAREN GUNNISON BALLEN Twenty-First Century Books Minneapolis In loving memory of Tamara Grace Ballen, 1948–2010 I thank Christine Zuchora-Walske for her editorial guidance.
    [Show full text]
  • 4149622.Pdf (4.408Mb)
    140 Reversing the Epidemic of HIV-1C in Southern Africa with Treatment as Prevention The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Essex, M. 2014. “140 Reversing the Epidemic of HIV-1C in Southern Africa with Treatment as Prevention.” Journal of Acquired Immune Deficiency Syndromes (1999) 65 (Suppl 2): 59. doi:10.1097/01.qai.0000446720.60423.1e. http:// dx.doi.org/10.1097/01.qai.0000446720.60423.1e. Published Version doi:10.1097/01.qai.0000446720.60423.1e Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12987279 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA TH 1515TH ANNANNUALUAL INTERNATIONAL MEETING INTERNATIONAL Center forHIV/AIDSPreventionandTreatment the Institute ofHumanVirology SEPTEMBER 8–12,2013|MOSCOW Global Virus Network Global Virus IHV is an Institute at the at Institute an IHV is and in partnershipwith The Moscow L INTERNATIONAL MEETING UA Institute of Human Virology in partnership with the Global Virus Network and The Moscow ANNUAL ANN Contents H T Center for HIV/AIDS Prevention and Treatment TH 5 1 15 SEPTEMBER 8 –12, 2013 | MOSCOW CONTENTS EVENTS SCHEDULE SPEAKER SCHEDULE ABSTRACTS INDEX CONTENTS Click on any content title to link to that section. 03 Program Information and Acknowledgements* *as of press time 16
    [Show full text]
  • Biomedicine, Commerce, and the CCR5 Gene Patent
    Intellectual Property and Molecular Biology: Biomedicine, Commerce, and the CCR5 Gene Patent Myles W. Jackson Caltech New York University Outline the Project CCR5 gene as a heuristic tool to probe the boundaries between science and society Biography of a scientific object (gene and its protein project) Genes as commodities: intellectual property and molecular biology BigPharma’s use of high-throughput screening (HTS) and structure-activity relationships (SARs) to identify and synthesize small molecules as inhibitors Genes and natural selection: resistance to disease ‘Race’ at the level of the DNA Age of ‘biocapitalism’ Introduction Stephenson-Wydler Technology Innovation Act of 1980 Bayh-Dole Act of 1980 Bill Clinton’s “Biotech Directive” of January 2001 The Human Genome Project What is at stake? The CCR 5 Story J. Craig Venter, Wallace Steinberg, and William Haseltine: HealthCare Investment Corporation, The Institute for Genomic Research (TIGR), and Human Genome Sciences (HGS) Yi Li and Steven M.Ruben, HGS Human G-protein chemokine receptor HDGNR 10: 6 June 1995 FASTA and BLAST: computer algorithms to find sequence homologies chemokines Research on the Receptor National Institutes of Health, Aaron Diamond AIDS Research Center-Rockefeller University, New York University School of Medicine, University of Pennsylvania School of Medicine, and Dana-Farber Cancer Institute HDGNR10 = CCR5= HIV-1 Co-Receptor CCR 5 The Brussels Group Euroscreen, Free University of Brussels, and U Penn School of Medicine: 32 mutation of the CCR5 gene: those who are homozygous for this allele are (by and large) immune to AIDS They file a patent application on the CCR5 gene and the 32 mutation (do not know about HGS’ application).
    [Show full text]
  • Croi 2021 Program Committee
    General Information CONTENTS WELCOME . 2 General Information General Information OVERVIEW . 2 CONTINUING MEDICAL EDUCATION . 3 CONFERENCE SUPPORT . 4 VIRTUAL PLATFORM . 5 ON-DEMAND CONTENT AND WEBCASTS . 5 CONFERENCE SCHEDULE AT A GLANCE . 6 PRECONFERENCE SESSIONS . 9 LIVE PLENARY, ORAL, AND INTERACTIVE SESSIONS, AND ON-DEMAND SYMPOSIA BY DAY . 11 SCIENCE SPOTLIGHTS™ . 47 SCIENCE SPOTLIGHT™ SESSIONS BY CATEGORY . 109 CROI FOUNDATION . 112 IAS–USA . 112 CROI 2021 PROGRAM COMMITTEE . 113 Scientific Program Committee . 113 Community Liaison Subcommittee . 113 Former Members . 113 EXTERNAL REVIEWERS . .114 SCHOLARSHIP AWARDEES . 114 AFFILIATED OR PROXIMATE ACTIVITIES . 114 EMBARGO POLICIES AND SOCIAL MEDIA . 115 CONFERENCE ETIQUETTE . 115 ABSTRACT PROCESS Scientific Categories . 116 Abstract Content . 117 Presenter Responsibilities . 117 Abstract Review Process . 117 Statistics for Abstracts . 117 Abstracts Related to SARS-CoV-2 and Special Study Populations . 117. INDEX OF SPECIAL STUDY POPULATIONS . 118 INDEX OF PRESENTING AUTHORS . .122 . Version 9 .0 | Last Update on March 8, 2021 Printed in the United States of America . © Copyright 2021 CROI Foundation/IAS–USA . All rights reserved . ISBN #978-1-7320053-4-1 vCROI 2021 1 General Information WELCOME TO vCROI 2021 Welcome to vCROI 2021! The COVID-19 pandemic has changed the world for all of us in so many ways . Over the past year, we have had to put some of our HIV research on hold, learned to do our research in different ways using different tools, to communicate with each other in virtual formats, and to apply the many lessons in HIV research, care, and community advocacy to addressing the COVID-19 pandemic . Scientists and community stakeholders who have long been engaged in the endeavor to end the epidemic of HIV have pivoted to support and inform the unprecedented progress made in battle against SARS-CoV-2 .
    [Show full text]
  • Board of Scientific Advisors Meeting Minutes of June 23-24, 2008
    NCIDEA: Board of Scientific Advisors Meeting Minutes of June 23-24, 2008 Site map Division of Extramural Activities Contact us Home | Funding | Advisory | NCI Research Priorities | Funded Awards | Research Resources | Events | NCI News Board of Scientific Advisors Meeting Minutes June 23-24, 2008 Building 31C, Conference Room 10 Bethesda, Maryland Quick Links The Board of Scientific Advisors (BSA), National Cancer Institute Members (NCI), convened for its 40th meeting on Monday, 23 June 2008, at Agenda & Future Meetings 8:00 a.m. in Conference Room 10, Building 31C, National Institutes of Health (NIH), Bethesda, MD. Dr. Robert C. Young, Meeting Minutes Chancellor, Fox Chase Cancer Center, presided as Chair. The BSA: Page 1 meeting was open to the public from 8:00 a.m. until 5:55 p.m. on 23 June for the NCI Director's report; report on NCI Congressional relations; ongoing and new business; recognition of departing members; a status report on nanotechnology; a report on linked investigator research in cancer biology; and consideration of request for applications (RFA) new and reissuance concepts and request for proposal (RFP) reissuance concepts presented by NCI Program staff. The meeting was open to the public from 8:30 a.m. on 24 June until adjournment at 11:40 a.m. for reports on The Cancer Genome Atlas (TCGA) and the Integrative Cancer Biology Program (ICBP). Board Members Present: Board Members Present: Dr. Robert C. Young (Chair) Dr. Edith A. Perez Dr. Paul M. Allen Dr. Richard L. Schilsk1y Dr. Christine Ambrosone Dr. Robert D. Schreiber Dr. Hoda Anton-Culver Dr. Stuart L.
    [Show full text]